[Alfadil--positive documentation when it comes to safety is missing].
Furberg
Curt
C
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA. cfurberg@wfubmc.edu
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004282:Documentation; D017292:Doxazosin / Q000009:adverse effects / Q000627:therapeutic use*; D004346:Drug Information Services; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D012307:Risk Factors; D012449:Safety
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D017292:Doxazosin